Abomics Appoints Sami Miettinen as New Chief Executive Officer from 01.05.2024

Turku, Finland, 26 April 2024 — Abomics is pleased to announce the appointment of Sami Miettinen as Chief Executive Officer (CEO) as of May 1st, 2024, succeeding former CEO Valter Rönnholm.

Sami joins Abomics from GE Healthcare, where he served as Global Marketing Director, Anesthesia and Respiratory Care business. Prior to that, he served in several global roles withing GE HealthCare and brings expertise in global marketing, product management and R&D.

Sami commentedI am excited to join Abomics to help drive the next phase of growth for the business. Abomics has an exceptional solution and great reputation in the field of pharmacogenetics and is uniquely positioned to support doctors in medication decisions and enabling precision medication for patients. Abomics is known for its professional team, and it is an honor to lead such an accomplished group of people.

Jari Forsström, Chief Medical Officer at Abomics statedWe are delighted to welcome Sami Miettinen as the new Chief Executive Officer at Abomics. Joining us from GE HealthCare, Sami brings a wealth of experience and leadership that will be invaluable as we accelerate growth and deliver long-term value for our expanding customer base across the pharmacogenomics field.

I would also like to take this opportunity to thank Valter Rönnholm for his leadership of Abomics which saw the organization achieve solid progress during challenging conditions.

Abomics collaborates with clinical laboratories to offer a pharmacogenetic test and interpretation report that helps doctors prescribe a medication and dosage based on the patient’s genetic characteristics. Abomics also produces medical and pharmaceutical databases, which support doctors in medication decisions.

Abomics acquired Multirec Oy in 2022. Multirec has over 20 years’ experience in delivering drug databases and drug related decision support to electronic patient records. Its good reputation and experience in collaboration with the leading electronic patient record vendors helps Abomics to create user-friendly integration of pharmacogenetics into clinical routines.

Jaa artikkeli: